Capgemini Stock Trails CAC 40, Under Pressure
Capgemini records the worst performance of the CAC 40 at mid-session on Wednesday, August 26, declining sharply while the Paris index advances. The stock falls below several technical benchmarks monitored since the publication of half-year results at the end of July, following a month that was nonetheless very bullish.
Capgemini Worst Performer in CAC 40 with a Decline of 2.7% During the Session
The Capgemini share drops 2.7% to €106.45 during the session, standing out as a downside exception in a CAC 40 gaining 0.47%. It is the strongest decline in the index at this moment. The context is mixed: over one month, the stock still shows a gain of nearly 18.5%, reflecting the rebound that began following its half-year results published on July 30, 2026.
However, over one year, the value declines by 14%, which puts the recent momentum into perspective. Today's decline brings the price to €106.45, a level that tests the coherence of the July rebound. The VIX, at 15.71 and nearly stable compared to the previous day, signals no particular tension on the markets: Capgemini's weakness is therefore specific to the stock, not a reflection of generalized risk aversion.
A Deteriorated Technical Configuration, Between the MA20 and Resistance at €111.40
The price falls below the MA20 at €107.82, with a gap of -1.27%, which interrupts the bullish momentum built since the end of July. The MA50 at €97.70 remains clearly below the price (gap of nearly 9%), offering medium-term support, but the MA200 at €112.34 continues to weigh above, at a gap of 5.24%. The RSI at 59 remains in neutral to slightly bullish territory, without signaling any excess. The resistance at €111.40 has not been broken through, and today's decline consolidates this failure in the short term.
The support identified at €86.06 remains very distant. On valuation, the stock trades at approximately 8.4 times expected earnings for the current fiscal year according to the analyst consensus, a moderate level that reflects the uncertainties weighing on restructuring costs. The stock remains under scrutiny in the €106 to €112 range, between the current price and resistance.
